HIF1A and colitis: Our results here suggest that miR-155 inhibits HIF-1α expression and thereby contributes to the intestinal barrier dysfunction in DSS-induced colitis, and highlights miR-155 antagomir and FG-4497 as potential therapeutic targets to treat human IBD.